ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.855
+0.125 (+0.79%)
As of 3:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close15.730
Open15.560
Bid15.780 x 1400
Ask15.790 x 1200
Day's Range15.390 - 15.940
52 Week Range14.510 - 41.200
Volume1,402,274
Avg. Volume3,098,200
Market Cap1.979B
Beta3.97
PE Ratio (TTM)N/A
EPS (TTM)-2.074
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.29
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology

    NEW YORK, NY / ACCESSWIRE / June 14, 2018 / U.S. markets fell Wednesday after the Federal Reserve raised interest rates and hinted at more increases were coming in 2018. The Dow Jones Industrial Average ...

  • Business Wire5 days ago

    ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018, at 11:30 a.m. Eastern Time in New York City. ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit10 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Business Wire12 days ago

    ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018, at 10:40 a.m. Pacific Time in Rancho Palos Verdes, California. ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

  • ACCESSWIRE17 days ago

    Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks

    Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR).

  • Is Acadia Pharmaceuticals (ACAD) a Buy?
    Motley Fool26 days ago

    Is Acadia Pharmaceuticals (ACAD) a Buy?

    Is there a silver lining in the dark clouds hovering over this biotech stock?

  • Better Buy: Acadia Pharmaceuticals vs. Biogen
    Motley Foollast month

    Better Buy: Acadia Pharmaceuticals vs. Biogen

    Which of these beaten-down biotech stocks is in better position to mount a strong comeback?

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ACAD earnings conference call or presentation 4-May-18 12:30pm GMT

    Q1 2018 ACADIA Pharmaceuticals Inc Earnings Call

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Business Wirelast month

    ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018, at 10:40 a.m. Pacific Time in Las Vegas. ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

  • Are These 2 Biotech Laggards Ready to Rebound?
    Motley Foollast month

    Are These 2 Biotech Laggards Ready to Rebound?

    Acadia Pharmaceuticals and Celgene Corporation have both significantly underperformed the broader market this year. Are they now outstanding bargains?

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Portola Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Pharmaceutical companies ACADIA and Portola saw their shares bursting on Friday. ACADIA moved higher on strong first quarter results of its Parkinson’s Disease drug Nuplazid while Portola soared higher after receiving FDA approval for Andexx, an anticoagulant-reversal antidote.

  • ACCESSWIRElast month

    Blog Exposure - Alnylam Pharma Attained Alignment with FDA on Pivotal Study Design for Lumasiran for Treatment of Primary Hyperoxaluria Type 1

    LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has reached agreement with the US Food and Drug Administration (FDA) on a pivotal study design evaluating lumasiran, an investigational RNAi therapeutic for the treatment of primary hyperoxaluria type 1 (PH1). Active-Investors.com is currently working on the research report for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), which also belongs to the Healthcare sector as the Company Alnylam Pharma.

  • Why Acadia Pharmaceuticals Jumped 11% Higher Today
    Motley Foollast month

    Why Acadia Pharmaceuticals Jumped 11% Higher Today

    First-quarter revenue growth has investors excited.

  • ACADIA Posts Narrower than Expected Loss in Q1, Sales Beat
    Zackslast month

    ACADIA Posts Narrower than Expected Loss in Q1, Sales Beat

    ACADIA posted narrower than expected loss in the first quarter of 2018 and sales beat estimates.

  • Associated Presslast month

    Acadia: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 44 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...

  • Business Wirelast month

    ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

    ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the first quarter ended March 31, 2018.

  • ACCESSWIRElast month

    ACADIA Pharmaceuticals Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 4, 2018 / ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 4, 2018 at 8:30 AM Eastern Time. ...

  • ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
    Business Wire2 months ago

    ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff, CFA, has been appointed to the newly created position of Senior Vice President, Investor Relations, leading investor and financial communications activities.

  • Will ACADIA (ACAD) Disappoint Investors This Earnings Season?
    Zacks2 months ago

    Will ACADIA (ACAD) Disappoint Investors This Earnings Season?

    ACADIA (ACAD) is expected to release first-quarter 2018 results on May 8 and provide updates on its drug, Nuplazid.

  • Business Wire2 months ago

    ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018 on Friday, May 4, 2018, before the U.S. financial markets open. ACADIA's management will host a conference call and webcast on Friday, May 4, 2018, at 8:30 a.m. Eastern Time to discuss ACADIA’s financial results and operations. The conference call may be accessed by dialing 844-821-1109 for participants in the United States or Canada and 830-865-2550 for international callers (reference passcode 3685527).

  • ACCESSWIRE2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Acadia Pharmaceuticals Inc. - ACAD

    NEW YORK, NY / ACCESSWIRE / April 27, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Acadia Pharmaceuticals Inc. ("Acadia"or the "Company") (ACAD). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Business Wire2 months ago

    ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced poster presentations of clinical experience data from two studies of NUPLAZID® (pimavanserin) in Parkinson’s disease psychosis (PD Psychosis) at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles.

  • Business Wire2 months ago

    ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID

    ACADIA Pharmaceuticals Inc. today issued the following statement:

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Dare Bioscience and ACADIA

    NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Dare Biosicence shares were exploding on Wednesday after the women's biopharma company announced that it had entered into an exclusive worldwide license agreement for Juniper Pharmaceutical's Intravaginal Ring technology platform. Shares of Arcadia didn't have as good a day as Dare yesterday as news of the FDA reviewing the company's controversial Parkinson's drug Nuplazid surfaced. Daré Bioscience, Inc. shares closed up 56.69% on Wednesday with around 29 million shares traded.